BioLife Solutions, Inc. expands upon its core biopreservation expertise to offer a comprehensive suite of cell processing tools for the biotechnology industry. The company's flagship products include CryoStor freeze media and HypoThermosol hypothermic storage media, which are optimized to preserve cells during regenerative medicine manufacturing. Its portfolio also features Sexton cell processing products, CellSeal cryogenic vials, and ThawSTAR automated thawing devices. Following the strategic divestiture of its cold chain logistics and freezer businesses in 2024 and 2025, BioLife transitioned into a pure-play cell processing company. Its consumables and instruments are specified in hundreds of active clinical trials and utilized in the majority of FDA-approved cell-based therapies, establishing a highly integrated position within the biopharma supply chain.
